Submicroscopic deletion of 5q involving tumor suppressor genes (CTNNA1, HSPA9) and copy neutral loss of heterozygosity associated with TET2 and EZH2 mutations in a case of MDS with normal chromosome and FISH results

Morteza Hemmat¹*, Weina Chen², Arturo Anguiano¹, Mohammed El Naggar¹, Frederick K Racke¹, Dan Jones³, Yongbao Wang³, Charles M Strom¹, Karl Chang¹ and Fatih Z Boyar¹

Abstract
Advances in genome-wide molecular cytogenetics allow identification of novel submicroscopic DNA copy number alterations (aCNAs) and copy-neutral loss of heterozygosity (cnLOH) resulting in homozygosity for known gene mutations in myeloid neoplasms. We describe the use of an oligo-SNP array for genomic profiling of aCNA and cnLOH, together with sequence analysis of recurrently mutated genes, in a patient with myelodysplastic syndrome (MDS) presenting with normal karyotype and FISH results. Oligo-SNP array analysis revealed a hemizygous deletion of 896 kb at chromosome 5q31.2, representing the smallest 5q deletion reported to date. The deletion involved multiple genes, including two tumor suppressor candidate genes (CTNNA1 and HSPA9) that are associated with MDS/AML. The SNP-array study also detected 3 segments of somatic cnLOH: one involved the entire long arm of chromosome 4; the second involved the distal half of the long arm of chromosome 7, and the third encompassed the entire chromosome 22 (UPD 22). Sequence analysis revealed mutations in TET2 (4q), EZH2 (7q), ASXL1 (20q11.21), and RUNX1 (21q22.3). Coincidently, TET2 and EZH2 were located at segments of cnLOH resulting in their homozygosity. Loss of heterozygosity affecting these two chromosomes and mutations in TET2 and EZH2 are indicative of a myelodysplastic syndrome with a poor prognosis. Deletion of the tumor suppressor genes CTNNA1 and HSPA9 is also likely to contribute to a poor prognosis. Furthermore, the original cnLOHs in multiple chromosomes and additional cnLOH 14q in the follow-up study suggest genetic evolution of the disease and poor prognosis. This study attests to the fact that some patients with a myelodysplastic syndrome who exhibit a normal karyotype may have underlying genetic abnormalities detectable by chromosomal microarray and/or targeted mutation analyses.

Keywords: Copy neutral loss of heterozygosity (cnLOH), Uniparental disomy (UPD), MDS, TET2, EZH2, RUNX1, EZH2, ASXL1, CTNNA1, HSPA9

Background
Recent advances in genome-wide molecular cytogenetics allow the identification of novel molecular abnormalities [1-8]. Emerging data demonstrate that myelodysplastic syndrome (MDS) exhibits abundant CNAs and cnLOH, often in the setting of a normal karyotype [9-11]. Loss of heterozygosity (LOH) is an indicator of neoplastic evolution and disease progression [12,13]. Copy-neutral LOH (cnLOH) arises either via a hemizygous deletion in one homolog and duplication of the other, or uniparental disomy (UPD). Both types of somatic LOH have been observed in studies of various cancer types and may explain some of the mechanisms by which tumor suppressor genes (TSGs) are inactivated or activating mutations in oncogenes are duplicated. Acquired UPD (aUPD) is now understood to be common in oncogenesis and appears to...
be a mechanism to increase the allelic burden of the mutated genes [14-24]. Thus, it is important to know the regions of cnLOH to determine new regions containing potential mutational targets affecting disease pathogenesis and treatment outcome [25,26].

Application of SNP-array technology has led to the identification of recurrent regions of cnLOH in a majority of the chromosomes [4,13,25,27-30] and recurrent pathogenic mutations. These findings have greatly advanced our understanding of the molecular mechanisms of cancer evolution and have led to the development of therapeutics and diagnostic tests. In this respect, mutation analysis helps further stratify neoplasms and their treatment outcome [31-34].

In this study, we used SNP array-based genomic profiling to detect acquired copy number alterations (aCNA) and cnLOHs, together with sequence analysis of genes commonly mutated in MDS, in a patient with normal chromosome and MDS FISH (fluorescence in situ hybridization) panel results.

Clinical presentation
Morphologic and immunophenotypic findings
An 88-year-old woman presented with leukocytosis (16.2×10^9/L) including minimal monocytosis (1.0×10^9/L), mild anemia (HGB 105 g/L), and moderate thrombocytopenia (79×10^9/L). Bone marrow morphologic and flow cytometric examinations revealed hypercellular bone marrow with granulocytic predominance with left-shifted and unusual maturation, and occasional atypical granulocytes and megakaryocytes, but no significant increase in monocytes or myeloblasts (Figure 1). A myeloid neoplasm positive for CD13 and CD33 was diagnosed, best classified as MDS, refractory cytopenia with multilineage dysplasia. Data on therapeutic interventions were not available for this study. At the 5-month follow-up, the overall morphologic and immunophenotypic findings were similar to those at initial presentation.

Chromosome and FISH study
Bone marrow cells were cultivated for 24 and 48 hours in RPMI 1640 or Marrow Max Medium with 10% fetal calf serum (Life Technologies, Grand Island, NY 14072, USA). In total, 20 mitoses were analyzed according to the ISCN (International System for Human Cytogenetic Nomenclature), with a resolution of 300 bands per haploid karyotype. FISH analyses using a panel of MDS probes (−5/5q−, −7/7q−, +8 and 20q−; Vysis, Downers Grove, IL, USA) and BlueGnome probes RP11-114B12 (Illumina, San Diego, CA, USA) for the deleted region 5q31.2 were performed on interphase cells according to the manufacturer’s protocol. Subsequently, 200 cells were examined carefully.

Oligo SNP array
Microdeletion/microduplication screening was performed using an SNP-array platform (CytoScan HD SNP array;
Affymetrix, Santa Clara, CA), following the manufacturer’s instructions. The CytoScan HD array has 2.67 million probes, including 1.9 million copy number probes and 0.75 million SNP probes. Array data were analyzed using the Chromosome Analysis Suite (ChAS) software v 2.0 (Affymetrix).

Mutation analysis
Genomic DNA was also tested for mutations in 19 genes that are recurrently mutated in myeloid neoplasms, including ASXL1, EZH2, RUNX1, IDH1, IDH2, KRAS, NRAS and TET2. Sequencing was performed using a TruSeq custom amplicon assay on the MiSeq sequencing platform (Illumina, Hayward, CA). Analysis was performed using SeqPilot software (JSI Medical Systems, Costa Mesa, CA). The assay had sufficient read depth to provide a minimum sensitivity of 5% to 10% for mutation detection.

Results and discussion
During the initial evaluation of the patient, cytogenetic analysis revealed a normal karyotype and FISH studies were negative for aCNAs commonly seen in MDS (MDS panel) (Figure 2A-D). Microarray analysis revealed a microdeletion of approximately 896 kb at the 5q31.2 chromosomal region and three segments of somatic cnLOH for the entire long arm of chromosome 4 (136 Mb), the distal half of the long arm of chromosome 7 (50 Mb), and the entire chromosome 22 (31 Mb). The microdeletion at 5q31.2 extended from 137,821,899 to 138,718,504 bp (UCSC genome Browser; http://genome.ucsc.edu/; hg19 release) and included the ETF1, HSPA9, SNORD63, CTNNA1, LRRTM2, SIL1, SNHG4, MATR3, SNORA74A, PAIP2, and SLC23A1 genes (Figure 3).

Of the genes deleted due to this microdeletion, two are tumor suppressor candidate genes associated with
MDS/AML: CTNNA1, which encodes alpha-1 catenin, and HSPA9, which encodes heat-shock 70-KD protein 9 (mortalin) [35]. Deletion of CTNNA1 was confirmed by applying BlueGnome FISH probes (RP11-114B12) (Figure 4). Alpha-catenins such as that encoded by CTNNA1 are essential for the regulation of cell-cell and cell-matrix interactions in tissues [36]. Loss of expression of the CTNNA1 tumor suppressor gene in hematopoietic stem cells may provide a growth advantage that contributes to human MDS/AML with 5q deletion [37]. Furthermore, loss of the CTNNA1 expression has been associated with leukemia progression or transformation of MDS to AML [38]. The HSPA9 gene is also located at the 5q31.2 region frequently deleted in MDS/AML, making it a candidate tumor suppressor gene; this is consistent with the biological function of its murine homologue. Human mortalin (encoded by HSPA9) was originally identified by its close homology to murine mortalins, which play important roles in cellular senescence [39]. The HSPA9 gene is a novel negative regulator of Raf/MEK/ERK pathway that may be a potential therapeutic target [40].

The combined size of cnLOHs spanning at least 10 Mb across the genome was approximately 217.6 Mb (Figure 5). These were detected at the long arm of chromosomes 4, 7, and 22. The cnLOH might result from mitotic recombination or nondisjunction which leads to segmental
or whole chromosomal UPD, respectively [13]. Acquired UPD (cnLOH) at diagnosis in our case is indicative of neoplastic evolution [12,13]. An additional UPD was identified at 14q in the follow-up study 5 months later, confirming the genetic progression of disease (Figure 6).

Recent investigations have indicated that cnLOH can be responsible for homozygosity of mutations in critical genes within the region. Reduction to homozygosity as a consequence of cnLOH was initially thought to be a mechanism for only inactivation of tumor suppressor genes [14,41,42]; however, identification of cnLOH in leukemia has shown that oncogenic mutations are also targeted [13,16,17].

Mutation analysis of 19 MDS-associated genes revealed an ASXL1 frameshift/stop mutation (Y591*, 41% of reads), an EZH2 point mutation (R690H, 85%), two RUNX1 frameshift/stop mutations (c.474dupT, 19% and c.424_425ins11bp, 7%), and two TET2 frameshift/stop mutations (c.1510_1513delAAAA, 77% and R1465*, 10%). These mutated genes are located on chromosomes 20, 7, 21, and 4, respectively. Recent studies have shown that TET2 mutations are present in up to 30% of MDS/MPN.

Figure 4 FISH inverted DAPI image showing deletion of the CTNNA1 gene using the BlueGnome FISH probe RP11-114B12 (5q31.2, red signal). The deleted chromosome 5 is indicated by an arrow.

Figure 5 SNP-array results at diagnosis showing loss of heterozygosity (LOH) at the long arm of chromosomes 4, 7, and 22 as purple bars next to the corresponding chromosomes.
cases, with mutations in *ASXL1, EZH2*, and *RUNX1* also commonly reported [43]. The finding of mutations in all four of these myeloid regulatory genes suggests that they play a critical role in the pathogenesis of this case and demonstrate that mutation analysis is useful in cytogenetically normal myeloid disorders [43].

The cnLOH affecting chromosome 7q and homozygous *EZH2* mutation have been reported in 10% of AML and MDS cases. They have been associated with a poor prognosis [9,26,44] and clonal evolution [45,46], supporting the possible role of *EZH2* as a tumor suppressor gene for myeloid malignancies.

In contrast to the mutated *TET2* and *EZH2* genes, no LOH was found for the other two mutated genes (*RUNX1* and *ASXL1*). *RUNX1* mutations have been proposed as clinically useful biomarkers to follow disease progression from MDS to AML as well as to monitor minimal residual disease (MRD) [47]. Moreover, *RUNX1* mutations were demonstrated to be frequent in *de novo* AML with non-complex karyotypes and conferred an unfavorable prognosis [48] explained by an association with resistance to chemotherapy [49].

Mutations in *ASXL1* have been identified in MDS, AML, chronic myeloid leukemia, chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia [50-54], and act as a tumor suppressor in myeloid malignancies [50]. Mutations in *ASXL1, TET2*, and *EZH2* have been found in 41% of MDS cases in a Chinese population [44], similar to the data reported in patients of European decent with MDS [21,23,24,55,56].

**Conclusion**

In conclusion, our study identified four large cnLOH and a microdeletion at 5q31 harboring two tumor suppressor genes (*CTNNA1* and *HSPA9*) in an MDS case with an apparently normal karyotype. The regions of cnLOH at chromosomes 4, 7, 14, and 22 confirm and extend previous studies, supporting that cnLOHs in myeloid disorders are common and nonrandom. Moreover, the presence of an additional aUPD 14q at follow up, along with persistence of
the 5q31 microdeletion and all cnLOHs detected at presentation, indicates genetic progression of the disease. The deletion of tumor suppressor genes CTNNA1 and HSPA9, along with mutation of candidate myeloid regulatory genes TET2 and EZH2, supports the diagnosis of MDS and likely portends a poor prognosis.

This study attests to the fact that some patients with a myelodysplastic syndrome exhibiting a normal karyotype may have underlying genetic abnormalities detectable by chromosomal microarray and/or targeted mutation analyses. Further genomic and molecular studies on a series of patients with MDS may yield information on how to stratify this category of disease to seek further molecular definition.

Ethical approval and consent

These studies were performed on anonymized samples received in the clinical laboratory and thus were exempted from the requirement for consent by an opinion for the Western Institutional Review Board.

Acknowledgments

The authors declare that they have no competing interests.

Conflict of interests

The authors declare that they have no competing interests.

Authors’ contributions

MH, First author; performed chromosome, FISH, and microarray analysis, performed the genomic sequencing. FR performed the comprehensive analysis. AA reviewed and reported the SNP-array analyses. MEN reviewed the manuscript. FZB reviewed and finalized the manuscript. All authors read and approved the final manuscript.

Annexes

acNA: Acquired copy number alteration; cnLOH: Loss of heterozygosity; aUPD: Acquired uniparental disomy.

Competing interests

The authors declare that they have no competing interests.

References

1. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Gittman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR: Genome-wide analysis of genetic alterations in acute lymphoblastic leukemia. Nature 2007, 446:758–764.

2. Suelz M, Alvarez S, Cifuentes F, Largo C, Ferreira BI, Bisla D, Ardanaz M, Garcia R, Marquez JA, Otero MD, Galaisan MG, Cigudosa JC: DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia 2007, 21:1224–1231.

3. Tsygina kinao A, Eliene E, Piippo K, Poffa K, Knuttia S: Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia. Leukemia 2007, 21:571–574.

4. Gupta M, Raghavan M, Gale RE, Chelala C, Allen C, Molloy G, Chaplin T, Linch DC, Cazier JB, Young BD: Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosomes Cancer 2008, 47:729–739.

5. Kawamata N, Ogawa S, Zimmermann M, Kato M, Sanada M, Hemininki K, Yamamoto G, Nannya Y, Koehler R, Florh T, Miller CW, Harbott J, Ludwig WD, Stanulla M, Schrappe M, Bantam CR, Koefler HP: Molecular allelokayotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 2008, 111(2):776–84.

6. Akagi T, Ogawa S, Dugas M, Kawamata N, Yamamoto G, Nannya Y, Sanada Miller CW, Yang A, Schnitger S, Haferlach T, Haferlach C, Koefler HP: Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica 2009, 94:213–223.

7. Maciejewski JP, Tu RV, O’Keefe C: Application of array based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. Br J Haematol 2009, 146:479–488.

8. Tu RV, Gondek LP, O’Keefe CL, Hunt J, Sekeres MA, Elson P, McDavit MA, Wang XF, Lewis MJ, Karp JE, Advani AS, Maciejewski JP: New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol 2009, 27:5219–5226.

9. Heinrichs S, Kulkarni RV, Buevos-Ramos CE, Levine RL, Loh ML, C, Neuberg D, Komblau SM, Isra JP, Gilliland DGC, Garcia-Manero G, Kantarjian HM, Estey EH, Ku AT: Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 2009, 23(8):1605–11.

10. Thiel A, Beier M, Ingenhah D, Senan K, Hein M, Moeller V, Betz B, Hildebrandt B, Evers C, Gemming U, Royer-Pokora B. Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance. Leukemia 2011, 25:287–359.

11. Tu RV, Gondek LP, O’Keefe CL, Elson P, Hunt J, McKenna J, Alusakaraj A, Advani AS, Paquette R, List AF, Sekeres MA, McDavit MA, Mulfi GJ, Maciejewski JP: Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011, 117(7):4552–60.

12. Anders C, Wuf C, Kusmacher M, Korsgaard M, Luerberg S, Lintorf TF: Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis 2007, 28(3):38–48.

13. Raghavan M, Smith LL, Lillington DM, Chaplin T, Kakka I, Molloy G, Chelala C, Cazier JB, Cavenagh JD, Fitzgibbon J, Lister TA, Young BD: Segregational uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood 2008, 112(8):1814–21.

14. Flotho C, Steindermann D, Mullighan CG, Neale G, Mayer K, Krapz CP, Schlegelberger B, Downing JR, Nernyart OM: Genome-wide single nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTNP11. Oncogene 2007, 26(39):5816–21.

15. Fitzgibbon J, Smith LL, Raghavan M, Smith ML, Debernardi S, Skoulakis L, Lillington D, Lister TA, Young BD: Association between acquired uniparental disomy and homzygous gene mutation in acute myeloid leukemias. Cancer Res 2005, 65:9152–9154.

16. Kalovics R, Passamonti F, Buser AS, Teo SS, Tieidt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352(17):1779–90.

17. Kalovics R, Guan Y, Pichall J: Uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002, 30(8):229–36.
nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008, 68(24):10349–57.

21. Ernst T, Chase AJ, Score J, Hidalgo-Curts CE, Bryant C, Jones AV, Waggon H, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Dunachon A, Gervansia F, Ocler D, Bodogai M, Grand FH, Cross NC. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010, 42(8):726–32.

22. Langemeijer SM, Kuiper RP, Berends M, Kuiper RP, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönnissen ER, et al. Molecular Cytogenetics ’23. Nikoloski G, Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Tönninnen ER, et al. van der Heijden A, Scheele TN, Vanbregen P, de Witte T, van der Reijden BA, Jansen JH. Somatic mutations of the histone methyltransferase gene EZH2 in myeloid syndromes. Nat Genet 2010, 42(8):665–7.

25. Mohamed A, Gaken J, Twine NA, Ingram W, Woomen L, Nc LC, Hayden J, Donlon N, Aul C, Gattermann N, Gaugouniers A, Gerning U, Löffler R, Löffler J, Löffler F, O’Reilly M, Dreyfus FJ, Schnittger S, Diker F, Kern W, Wendland N, Sundermann J, Alpermann T, Pellagatti A, McGraw K, Trubia M, Pelicci PG, Di Fiore PG. Somatic loss of heterozygosity without loss of genetic material at 5q31. Cancer Res 2012, 72(7):1857–63.

26. Dittmore RW, Putt J, Putt J, O’Reilly CL, Sekeres MA, Thiel KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS. Blood 2008, 111(15):342–7.

27. Corletta TA, Garparini P, DiEliess MM, Trubia M, Pelicci PG, Di Fiore PG: Frequent loss of heterozygosity without loss of genetic material in acute myeloid leukemia with a normal karyotype. Cancer Res 2005, 65:3175–3180.

28. Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ, Fizgibbons J, Smith ML, Debernardi S, Skoulakis S, Lillington D, Lister TA, Young BD. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005, 65:9152–9154.

29. Gondex LP, Tu, R, O’Keefe CL, Sekeres MA, Thiel KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS. Blood 2008, 111(15):342–7.

30. Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T, Pellagatti A, McGraw K, Muramatsu H, Molteno AR, Sekeres MA, McDevitt MA, Koijima S, List A, Bouthoum J, Muffli GJ, Maciejewski JP. Loss of heterozygosity in 7q myelodysplasia syndromes: clinical associations and genomic pathogenesis. Blood 2012, 119(25):6109–17.

31. Jankowska AM, Szpukha T, Liu T, Makishima H, Arai M, Ueda H, O’Keefe CL, Genetzy R, McDevitt MA, Maciejewski JP. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113(20):6403–10.

32. Wang L, Ali X, Gale RP, Xu Z, Qin T, Fang L, Zhang H, Pan L, Hu N, Zhang Y, Xiao Z, TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leuk Res 2013, 37(3):305–11.

33. Jereb A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychoden B, Visconte T, Liu T, O’Keefe CL, Mohamed AM, Makishima H, Morlat R, Ectors K, Colombo E, Santucci A, Bigerna B, Pacini A, Puccinelli A, Misasi A, Fabbri A, Meani N, Pettirossi V, Saggin S, Mardini F, Lo-Cocco F, Dellorusso L, Marchon A, Casadevall N, Lacombe C, Roma Sp, Dessen P, Soulier J, Vigué F, Fontenay M, Vainchenker W, Bernard OA. Mutation in TET2 in myeloid malignancies. Nat. Engl J Med, 2009, 360(22):2289–301.
52. Boulwood J, Perry J, Zaman R, Fernandez-Santamaria C, Littlewood T, Kusec R, Pellagatti A, Wang L, Clark RE, Wainscoat JS: High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. *Leukemia* 2010, 24(6):1139–45.

53. Pérez B, Kosmider O, Cassinat B, Rennevile A, Lachenaud J, Kaltenbach S, Bertrand Y, Baruchel A, Chomienne C, Fontenay M, Preudhomme C, Cavé H: Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. *Br J Haematol* 2010, 151(5):460–8.

54. Sugimoto Y, Muramatsu H, Makishima H, Prince C, Jankowska AM, Yoshida N, Xu Y, Nishio N, Hama A, Yagasaki H, Takahashi Y, Kato K, Marabe A, Kojima S, Mariejean JP: Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. *Br J Haematol* 2010, 150(1):83–7.

55. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Vigué F, Quenel B, Beyne-Rouzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mars V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M, Groupe Francophone des Myélodysplasies: TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). *Blood* 2009, 114(15):3285–91.

56. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A, Wichmann M, Göhring G, Schumann C, Bug G, Otmann O, Hofmann WK, Schlegelberger B, Heuser M, Ganser A: Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. *J Clin Oncol* 2011, 29(18):2499–506.

doi:10.1186/1755-8166-7-35

Cite this article as: Hemmat et al.: Submicroscopic deletion of 5q involving tumor suppressor genes (CTNNA1, HSPA9) and copy neutral loss of heterozygosity associated with TET2 and EZH2 mutations in a case of MDS with normal chromosome and FISH results. *Molecular Cytogenetics* 2014 7:35.